发布求助
文献互助 智能选刊 最新文献

European Journal of Cancer and Clinical Oncology最新文献

筛选
英文 中文
Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura α干扰素治疗特发性血小板减少性紫癜
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90577-Z
Stephen J. Proctor
{"title":"Alpha interferon therapy in the treatment of idiopathic thrombocytopenic purpura","authors":"Stephen J. Proctor","doi":"10.1016/0277-5379(91)90577-Z","DOIUrl":"10.1016/0277-5379(91)90577-Z","url":null,"abstract":"<div><p>Treatment of patients with idiopathic thrombocytopenic purpura (ITP) varies according to the severity of the condition, the patient's age and the phase of the disease. The mainstay of treatment is corticosteroid therapy, with splenectomy for non-responding patients. For the 5%–10% of patients with refractory disease and bleeding problems, intravenous immunoglobulins are often used. Danazol achieves a response in about 30%–40% of refractory patients. At our centre, we have now treated 13 patients with interferon alfa-2b, all of whom had severe steroid-unresponsive ITP of various durations. All patients received 12 injections of 3 million units (MU) interferon subcutaneously three times a week. The platelet count rose significantly in 10 patients after interferon therapy and in one patient during therapy. Three patients had a complete response and eight a partial response. One complete responder relapsed at 5 months but again responded to retreatment with interferon. Responses were similar in splenectomized and non-splenectomized patients, and platelet-associated immunoglobulin levels remained essentially unchanged. Based on a compilation of data from this and other studies, the positive response rate (platelets at least 30–200 × 10<sup>9</sup>/L for at least 6 weeks) is 69% (<span><math><mtext>22</mtext><mtext>32</mtext></math></span> patients). The future role and dosage of interferon in ITP remains to be determined and particularly in direct comparison with intravenous IgG therapy.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S63-S68"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90577-Z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial in progress 干扰素α -2b加氯霉素治疗滤泡性淋巴瘤:一项正在进行的随机试验的初步结果
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90567-W
Christopher G.A. Price , Ama Z.S. Rohatiner , William Steward , David Deakin , Nigel Bailey , Andrew Norton , George Blackledge , Derek Crowther , T. Andrew Lister
{"title":"Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial in progress","authors":"Christopher G.A. Price ,&nbsp;Ama Z.S. Rohatiner ,&nbsp;William Steward ,&nbsp;David Deakin ,&nbsp;Nigel Bailey ,&nbsp;Andrew Norton ,&nbsp;George Blackledge ,&nbsp;Derek Crowther ,&nbsp;T. Andrew Lister","doi":"10.1016/0277-5379(91)90567-W","DOIUrl":"10.1016/0277-5379(91)90567-W","url":null,"abstract":"<div><p>One hundred and twenty four patients with follicular lymphoma (32 with Stage III and 92 with Stage IV disease) have been randomized to receive chlorambucil alone or chlorambucil plus interferon alfa-2b. Responding patients are then randomized to receive either interferon alfa-2b maintenance therapy for up to 12 months or no further treatment. One hundred and eight patients are evaluable for response, the remainder are still receiving initial therapy. Clinical remission (complete or good partial remission) was achieved in <span><math><mtext>42</mtext><mtext>59</mtext></math></span> (71%) patients receiving chlorambucil alone and in <span><math><mtext>27</mtext><mtext>49</mtext></math></span> (55%) patients receiving the combination (<em>P</em> = NS). Preliminary analysis of remission duration shows a trend in favour of those patients receiving interferon throughout (<em>P</em> = 0.02). There is no significant difference between the groups in terms of survival, at a median follow up of 2.5 years. Interferon-associated toxicity was minor in most patients but led to discontinuation of therapy in six cases. Larger trials with longer follow-up periods are needed to confirm the beneficial role of interferon in the treatment of follicular lymphoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S34-S36"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90567-W","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Panel discussion 小组讨论
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90587-4
{"title":"Panel discussion","authors":"","doi":"10.1016/0277-5379(91)90587-4","DOIUrl":"https://doi.org/10.1016/0277-5379(91)90587-4","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Page S92"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90587-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138353245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interferon alfa-2b in stage A untreated B-chronic lymphocytic leukaemia patients 干扰素α -2b在A期未经治疗的b -慢性淋巴细胞白血病患者中的作用
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90581-W
Viki A. Boussiotis , Gerassimos A. Pangalis
{"title":"Interferon alfa-2b in stage A untreated B-chronic lymphocytic leukaemia patients","authors":"Viki A. Boussiotis ,&nbsp;Gerassimos A. Pangalis","doi":"10.1016/0277-5379(91)90581-W","DOIUrl":"10.1016/0277-5379(91)90581-W","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S78-S79"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90581-W","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12961546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Alveolar macrophage function before and during treatment with cytotoxic chemotherapy in patients with small cell lung cancer 小细胞肺癌患者细胞毒性化疗前后肺泡巨噬细胞功能的变化
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90454-L
H.S.R. Hosker , P. McArdle , P.A. Corris
{"title":"Alveolar macrophage function before and during treatment with cytotoxic chemotherapy in patients with small cell lung cancer","authors":"H.S.R. Hosker ,&nbsp;P. McArdle ,&nbsp;P.A. Corris","doi":"10.1016/0277-5379(91)90454-L","DOIUrl":"10.1016/0277-5379(91)90454-L","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Page 1711"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90454-L","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12829438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma 神经母细胞瘤磁共振成像、间碘苄基胍显像和骨髓组织学/细胞学的前瞻性比较
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90415-A
Robin Corbett , Julie Olliff , Neil Fairley , Judy Moyes , Janet Husband , Ross Pinkerton , Richard Carter , Jennifer Treleaven , Timothy McElwain , Simon Meller
{"title":"A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma","authors":"Robin Corbett ,&nbsp;Julie Olliff ,&nbsp;Neil Fairley ,&nbsp;Judy Moyes ,&nbsp;Janet Husband ,&nbsp;Ross Pinkerton ,&nbsp;Richard Carter ,&nbsp;Jennifer Treleaven ,&nbsp;Timothy McElwain ,&nbsp;Simon Meller","doi":"10.1016/0277-5379(91)90415-A","DOIUrl":"10.1016/0277-5379(91)90415-A","url":null,"abstract":"<div><p>A prospective comparison between magnetic resonance imaging (MRI), <sup>123</sup>I meta-iodobenzylguanidine (mIBG) scintigraphy and posterior iliac crest marrow aspiration and trephine biopsy in 30 assessments (19 patients) showed concordance between the three techniques in 16 assessments (53.3%). In 10 (33.3%), MRI and mIBG revealed abnormalities not detected by marrow biopsy. MRI was the only technique to demonstrate marrow abnormality in four assessments (13.3%). In addition, MRI revealed more sites of abnormality in 16 parallel assessments. We conclude that MRI shows promise as a non-invasive means of detecting bone marrow infiltration by neuroblastoma, but that further evaluation of the specificity of MRI in this setting is indicated.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1560-1564"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90415-A","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 39
New anthracycline derivatives: What for? 新的蒽环类衍生物:用于什么?
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90409-7
Klaus Mross
{"title":"New anthracycline derivatives: What for?","authors":"Klaus Mross","doi":"10.1016/0277-5379(91)90409-7","DOIUrl":"10.1016/0277-5379(91)90409-7","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1542-1544"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90409-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12943909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Homoeostatic response criteria for cancer therapy 癌症治疗的稳态反应标准
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90459-Q
Erik Hippe , Viggo Jønsson , Hans von der Maase , Jens Christian Mathiesen , Hans Skovgaard Poulsen
{"title":"Homoeostatic response criteria for cancer therapy","authors":"Erik Hippe ,&nbsp;Viggo Jønsson ,&nbsp;Hans von der Maase ,&nbsp;Jens Christian Mathiesen ,&nbsp;Hans Skovgaard Poulsen","doi":"10.1016/0277-5379(91)90459-Q","DOIUrl":"10.1016/0277-5379(91)90459-Q","url":null,"abstract":"","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1715-1716"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90459-Q","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12944356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma 替尼泊苷治疗艾滋病相关卡波西肉瘤的II期研究
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90434-F
G. Schwartsmann, E. Sprinz, M. Kronfeld, J. Vinholes, E. Sander, M. Zampese, R. Preger, L. Kalakun, A.L. Brunetto
{"title":"Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma","authors":"G. Schwartsmann,&nbsp;E. Sprinz,&nbsp;M. Kronfeld,&nbsp;J. Vinholes,&nbsp;E. Sander,&nbsp;M. Zampese,&nbsp;R. Preger,&nbsp;L. Kalakun,&nbsp;A.L. Brunetto","doi":"10.1016/0277-5379(91)90434-F","DOIUrl":"10.1016/0277-5379(91)90434-F","url":null,"abstract":"<div><p>Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30–80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m<sup>2</sup> every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6–20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1637-1639"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90434-F","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12945232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Phase II study of nimustine in metastatic soft tissue sarcoma 尼莫司汀治疗转移性软组织肉瘤的II期研究
European Journal of Cancer and Clinical Oncology Pub Date : 1991-12-01 Epub Date: 2004-04-15 DOI: 10.1016/0277-5379(91)90424-C
D.J.Th. Wagener , R. Somers , A. Santoro , J. Verweij , P.J. Woll , G. Blackledge , H.J. Schütte , M.A. Lentz , M. van Glabbeke , European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
{"title":"Phase II study of nimustine in metastatic soft tissue sarcoma","authors":"D.J.Th. Wagener ,&nbsp;R. Somers ,&nbsp;A. Santoro ,&nbsp;J. Verweij ,&nbsp;P.J. Woll ,&nbsp;G. Blackledge ,&nbsp;H.J. Schütte ,&nbsp;M.A. Lentz ,&nbsp;M. van Glabbeke ,&nbsp;European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","doi":"10.1016/0277-5379(91)90424-C","DOIUrl":"10.1016/0277-5379(91)90424-C","url":null,"abstract":"<div><p>The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m<sup>2</sup> every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1604-1605"},"PeriodicalIF":0.0,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90424-C","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12945225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书